FDA Grants Orphan Drug Designation to MicuRx’s MRX-5 for NTM Infections

SHANGHAI, Jan. 1, 2025 /PRNewswire/ — Shanghai MicuRx Pharmaceutical Co., Ltd. (“MicuRx”，688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of…